Savara Inc (SVRA) Stock Price, Quote & News

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 512 614 1848

Website: www.savarapharma.com

Address:

1717 Langhorne Newtown Road, Suite 300, Langhorne, United States

UgoGreg Jan. 6 at 11:46 PM

$SVRA https://youtu.be/ygBN8MilTyc

0 · Reply

Richterscale Jan. 6 at 7:51 PM

$SVRA 2 day pullback like last one then buy it back. Let’s see if it repeats again

0 · Reply

PLATINUM_TRADES Jan. 6 at 5:20 AM

$SVRA The 10 at $6.17 looks good after a dip looks to bounce soon🚨🚨

0 · Reply

Zeffanator2 Jan. 5 at 2:51 AM

$SVRA This is the last stock that is pump and dump. Gotta call out moronic comments.

0 · Reply

ghostdemon Jan. 2 at 6:56 PM

$SVRA pump and dump fraud

0 · Reply

KPMD Jan. 2 at 4:45 PM

$SVRA Now we’re testing our support level on anemic volume. I think this is a good thing washing out the weak hands. I’m optimistically cautious that this level should hold , and if it does, it’ll be a new into the 7 to 8 dollar range.

0 · Reply

Richterscale Dec. 30 at 8:07 PM

$SVRA Profit takers or manipulation..or both?

2 · Reply

Spacemonkey1 Dec. 29 at 7:59 PM

$SVRA the FDA has to tell you if you’ve got priority review within 60 days from submission of the BLA

0 · Reply

Richterscale Dec. 28 at 5:00 PM

$SVRA

0 · Reply

IN0V8 Dec. 26 at 7:12 PM

$SVRA Watch H.C. Wainwright raises target price to $10

0 · Reply

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 17, 2025, 8:05 AM EST - 21 days ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 8:05 AM EST - 27 days ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 2, 2025, 8:05 AM EST - 5 weeks ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Nov 20, 2025, 4:05 PM EST - 6 weeks ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Nov 16, 2025, 6:35 AM EST - 7 weeks ago

Savara: A High-Risk Opportunity

Nov 12, 2025, 4:05 PM EST - 2 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 5:54 PM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Oct 31, 2025, 4:05 PM EDT - 2 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 30, 2025, 11:05 AM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 29, 2025, 9:43 PM EDT - 2 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 4:07 PM EDT - 2 months ago

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 2 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 28, 2025, 9:58 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 17, 2025, 8:05 AM EDT - 2 months ago

Savara Announces Chief Medical Officer (CMO) Transition

Oct 14, 2025, 12:14 PM EDT - 3 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 12, 2025, 8:44 AM EDT - 3 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 9, 2025, 7:42 AM EDT - 3 months ago

Savara: Back On Track With Upcoming APAP BLA Filing

Oct 6, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 2, 2025, 4:05 PM EDT - 3 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Sep 29, 2025, 2:00 AM EDT - 3 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 2, 2025, 9:00 AM EDT - 4 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Aug 20, 2025, 5:15 PM EDT - 5 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 18, 2025, 8:05 AM EDT - 5 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 13, 2025, 8:05 AM EDT - 5 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Jul 18, 2025, 4:05 PM EDT - 6 months ago

Savara Announces New Employment Inducement Grant

May 28, 2025, 6:00 AM EDT - 8 months ago

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

UgoGreg Jan. 6 at 11:46 PM

$SVRA https://youtu.be/ygBN8MilTyc

0 · Reply

Richterscale Jan. 6 at 7:51 PM

$SVRA 2 day pullback like last one then buy it back. Let’s see if it repeats again

0 · Reply

PLATINUM_TRADES Jan. 6 at 5:20 AM

$SVRA The 10 at $6.17 looks good after a dip looks to bounce soon🚨🚨

0 · Reply

Zeffanator2 Jan. 5 at 2:51 AM

$SVRA This is the last stock that is pump and dump. Gotta call out moronic comments.

0 · Reply

ghostdemon Jan. 2 at 6:56 PM

$SVRA pump and dump fraud

0 · Reply

KPMD Jan. 2 at 4:45 PM

0 · Reply

Richterscale Dec. 30 at 8:07 PM

$SVRA Profit takers or manipulation..or both?

2 · Reply

Spacemonkey1 Dec. 29 at 7:59 PM

$SVRA the FDA has to tell you if you’ve got priority review within 60 days from submission of the BLA

0 · Reply

Richterscale Dec. 28 at 5:00 PM

$SVRA

0 · Reply

IN0V8 Dec. 26 at 7:12 PM

$SVRA Watch H.C. Wainwright raises target price to $10

0 · Reply

Zeffanator2 Dec. 25 at 3:21 AM

$SVRA LFG after the New Year. This has only cruised North over the past few months. Shouldn’t be any Nay Sayers at this point. 11 bucks would be nice come end of January. 🎅

0 · Reply

Spacemonkey1 Dec. 24 at 7:03 PM

$SVRA next catalyst is priority review, that shortens time from 12 to 6 months. I think that’s going to be the difference between hanging out probably in the 4s or 5s for 6-8 months versus being in the 6s for 3 months then rising pre-approval.

1 · Reply

KPMD Dec. 24 at 2:34 PM

$SVRA It is interesting The M&A space for small cap biotech is going on. This morning, Sanofi just bought DVAX , hepatitis B vaccine company for $2.4 billion I think we’re in the right price point for something to look at us to be purchased.

0 · Reply

TitaniumTrade Dec. 24 at 11:49 AM

$SVRA Future price discovery depends on how execution velocity aligns with stated operational milestones. Momentum requires evidence, not projections.

0 · Reply

WallStreetBuyDip Dec. 23 at 5:17 PM

my $SVRA watchlist setup. patience until H% is very low like this.

0 · Reply

ckruel Dec. 23 at 3:28 PM

$SVRA H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Savara (SVRA) to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.

0 · Reply

PnLViewCoreX_1377 Dec. 23 at 1:26 PM

$SVRA biotech coiling, watch for trend confirmation only if volume expands on the break

0 · Reply

mikesterz7 Dec. 23 at 12:32 PM

$SVRA 🚨 Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

0 · Reply

erevnon Dec. 23 at 12:21 PM

HC Wainwright & Co. maintains Savara $SVRA at Buy and raises the price target from $8 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DARKP00L Dec. 23 at 11:52 AM

$SVRA 06:44 on Dec. 23 2025 HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $10 #tradeideas

0 · Reply

JarvisFlow Dec. 23 at 11:42 AM

HC Wainwright & Co. has adjusted their stance on Savara ( $SVRA ), setting the rating to Buy with a target price of 8 → 10.

0 · Reply

Richterscale Dec. 23 at 2:52 AM

$SVRA https://www.marketbeat.com/instant-alerts/savara-inc-nasdaqsvra-receives-average-rating-of-moderate-buy-from-brokerages-2025-12-17/

0 · Reply

Market Cap	1.15B
Revenue (ttm)	0.00
Net Income (ttm)	-95.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,445,000
Avg Vol	2,854,844
Day's Range	N/A - N/A
Shares Out	203.47M
Stochastic %K	26%
Beta	0.28
Analysts	Strong Sell
Price Target	$10.94